TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $12.08 Consensus Price Target from Analysts

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have received an average rating of “Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $12.08.

Several research firms recently issued reports on TLSI. Oppenheimer started coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 price objective for the company. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Roth Mkm initiated coverage on TriSalus Life Sciences in a research report on Monday, November 11th. They issued a “buy” rating and a $11.00 price objective for the company. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Finally, Northland Securities started coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target for the company.

TriSalus Life Sciences Stock Up 6.1 %

Shares of NASDAQ:TLSI opened at $4.32 on Wednesday. TriSalus Life Sciences has a 52-week low of $3.61 and a 52-week high of $10.42. The stock has a market cap of $131.73 million, a P/E ratio of -1.73 and a beta of 0.49. The business has a fifty day moving average of $4.24 and a two-hundred day moving average of $5.49.

Insider Activity

In other news, CEO Mary T. Szela purchased 7,520 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the purchase, the chief executive officer now directly owns 377,382 shares of the company’s stock, valued at $1,962,386.40. The trade was a 2.03 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have purchased 19,560 shares of company stock worth $95,190. Corporate insiders own 32.80% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of TLSI. Virtu Financial LLC purchased a new position in TriSalus Life Sciences in the third quarter valued at $92,000. Geode Capital Management LLC increased its holdings in shares of TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares during the last quarter. Vestcor Inc acquired a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth about $108,000. MSD Partners L.P. purchased a new stake in TriSalus Life Sciences during the third quarter worth approximately $184,000. Finally, Walleye Capital LLC acquired a new position in TriSalus Life Sciences in the third quarter valued at approximately $66,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.